ABSTRACT
RESUMEN Introducción: Las bradiarritmias persistentes que requieren el implante de un marcapasos definitivo son una complicación frecuente tras el implante valvular aórtico percutáneo (IVAP), pero un implante alto con técnica Cusp-Overlap podría evitar las alteraciones del sistema de conducción. Objetivo: El objetivo fue determinar la tasa de uso de marcapasos en pacientes que recibieron IVAP con la técnica convencional coplanar en comparación con Cusp-Overlap. Material y métodos: Entre 2017 y 2019 se analizaron 65 pacientes consecutivos de dos centros, que recibieron válvulas EvolutR o Evolut-Pro: 50 implante coplanar y 15 Cusp-Overlap. Resultados: La edad promedio era 80 años y no hubo diferencias en el riesgo por puntaje EuroSCORE. Los procedimientos con la técnica de Cusp-Overlap presentaron 0% de requerimiento de marcapasos en comparación con 24,9% en el implante convencional (p = 0,041). También hubo menos complicaciones mayores (6,67% vs 42%; OR = 0,09; IC 95% 0,01-0,8; p = 0,011). Conclusiones: En esta cohorte el IVAP con la técnica de Cusp-Overlap se asoció con una necesidad de marcapasos nula. Dado el potencial impacto a gran escala se necesita validar externamente los resultados obtenidos.
ABSTRACT Background: Persistent bradyarrhythmias requiring permanent pacemaker implantation are a common complication after transcatheter aortic valve implantation (TAVI), but high implantation with cusp-overlap technique could prevent conduction system disturbances. Objective: The aim of this study was to assess the rate of pacemaker use in patients who received TAVI with conventional coplanar technique compared with cusp-overlap technique. Methods: A total of 65 consecutive patients from two centers receiving Evolut-R or Evolut-Pro valve implantation, 50 coplanar and 15 cusp-overlap, were analyzed between 2017 and 2019. Results: Mean age was 80 years, and there were no differences in risk according to the EuroSCORE. The rate of pacemaker requirement was 0% in cusp-overlap procedures compared with 24.9% in those with conventional implantation; p=0.041). In addition, cusp-overlap implants presented lower rate of major complications (6.67% vs. 42%; OR=0.09; 95% CI 0.01-0.8; p=0.011). Conclusions: In this cohort, TAVI procedure with cusp-overlap technique was associated with null pacemaker requirement. Given the potential large-scale impact, external validation of results is needed.
ABSTRACT
Abstract Objective: The EX-PRESS device is a surgical alternative for the treatment of POAG. To describe the IOP behavior before and after the implantation of the EX-PRESS, the pharmacological treatment used in the pre and postoperative period and the complications in the first year of the postoperative period. Methods: A quantitative descriptive study with review of electronic medical records of a private ophthalmological reference hospital in Goiânia (GO) from 2013 to 2018. Sample composed of 8 eyes with POAG subjected to the EX-PRESS implant. We observed the variables: gender, age, operated eye, antiglaucomatous medications used, pre and postoperative intraocular pressure, and possible complications. Results: In the preoperative period, all eyes used antiglaucomatous drops, 75% used 3 or more different classes simultaneously. After 12 months of EX-PRESS, only 12.5% used three or more eye drops and 37.5% did not use any eye drops. On average, IOP varied from 18.63mmHg (SD 9.38) in the preoperative period to 14.50mmHg (SD 4.14) at 12 months postoperatively. Complications were: ocular hypotension, ocular hypertension; thinning of the conjunctival blister, cystic blister obstruction of the EX-PRESS. We resolved all coplications. Conclusion: The efficacy of EX-PRESS in IOP reduction was verified in the study. Concomitantly, there was a considerable decrease in anti-glaucomatous medications, and few associated complications.
Resumo Objetivo: O dispositivo EX-PRESS é uma alternativa cirúrgica para o tratamento do GPAA. Descrever o comportamento da PIO antes e após a implantação do EX-PRESS, o tratamento farmacológico utilizado no período pré e pós-operatório e as complicações no primeiro ano do pós-operatório. Métodos: Estudo descritivo quantitativo com revisão de prontuários eletrônicos de um hospital particular de referência oftalmológica de Goiânia (GO) no período de 2013 a 2018. Amostra composta por 8 olhos com GPAA submetidos ao implante de EX-PRESS. Foram observadas variáveis: sexo, idade, olho operado, medicações antiglaucomatosas usadas, pressão intraocular pré e pós-operatória, e possíveis complicações. Resultados: No pré-operatório, todos os olhos usavam colírios antiglaucomatosos, 75% faziam uso simultâneo de 3 ou mais classes diferentes. Após 12 meses do EX-PRESS, apenas 12,5% usavam três ou mais colírios e 37,5% não usavam nenhum colírio. Em média, as PIO variaram de 18,63 (DP 9,38) mmHg no pré-operatório para 14,50 (DP 4,14) mmHg em 12 meses do pós-operatório. As complicações foram: hipotensão ocular, hipertensão ocular,afinamento de bolha conjuntival, bolha cística, obstrução parcial do EX-PRESS. Conclusão: A eficácia do EX-PRESS na redução da PIO foi verificada na amostra desse estudo. Concomitantemente, constatou-se diminuição considerável de medicações anti-glaucomatosas, e poucas complicações associadas.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Glaucoma, Open-Angle/surgery , Glaucoma Drainage Implants , Intraocular Pressure/physiology , Tonometry, Ocular/instrumentation , Electronic Health RecordsABSTRACT
Abstract Objective: The aim of this retrospective study is to evaluate the safety and performance of the Perceval sutureless valve in patients undergoing aortic valve replacement. We report the 30-day clinical outcomes of 139 patients. Methods: From January 2014 to December 2016, 139 patients underwent sutureless aortic valve replacement. Their operation notes, National Adult Cardiac Surgery Database and perioperative transoesophageal echocardiography findings were studied retrospectively. Results: Ninety-two patients underwent isolated aortic valve replacement (group A) with Perceval valve and 47 patients had combined procedures of aortic valve replacement and coronary artery bypass grafting (group B). The patients received a size S (n=23), M (n=39), L (n=42) or XL (n=35) prosthesis. Perceval valve was successfully implanted in 135 (97.1%) patients. Mean cross-clamping time and bypass time were 40 and 63 minutes for isolated cases, while 68 and 107 minutes for combined cases. Three (2.1%) patients died within 30 days. Four patients suffered stroke and 5 patients went into acute renal failure. Median intensive care unit and hospital stay was 2 and 8.5, respectively. Four valves were explanted due to significant paravalvular leak after surgery. Five patients had permanent pacemaker as a result of complete heart block and mean postoperative drainage was 295 mL for isolated case and 457 mL for combined cases. The mean gradient across Perceval valve was 12.5 mmHg while its effective orifice area was 1.5 cm2. Conclusion: Early postoperative results showed that Perceval valve is safe. Further follow up is needed to evaluate the long-term outcome with this bioprosthesis.